Peering into the Future

Connectomics and the Pharmaceutical Industry

Abstract:

Connectomics, the mapping of neural connections and brain functions, can potentially revolutionise drug discovery. By understanding brain circuitry, researchers can identify novel drug targets, elucidate disease mechanisms, and predict drug efficacy. This approach holds immense potential for personalized medicine, enabling tailored treatments based on individual brain connectivity. 

1. Dr. Agrawal, your work blends neuroscience and artificial intelligence. How has this interdisciplinary approach shaped your understanding of connectomics and its role in pharmaceutical research?

Traditionally, outcomes in brain-related disorders are assessed by tracking symptom improvement or by examining drug interactions at the cellular level. While these approaches are valuable, they provide only a localised picture, making it difficult to capture the cascade of changes triggered across the brain. The brain functions as an intricate, dynamic network—a mesh so complex that we are still far from fully understanding it.

What fascinates me is the gap between drug development and our ability to evaluate its effects on the brain as a whole system. This is where connectomics becomes transformative. By studying brain connectivity at different scales—micro, meso, and macro—we can move beyond symptom-based measures and gain an objective framework to understand how interventions reshape brain networks. In particular, macro-connectomics offers a powerful validation layer, allowing us not only to track therapeutic impact but also to anticipate potential side effects.

By integrating neuroscience with artificial intelligence, we can begin to map these hidden network-level dynamics with greater precision. This interdisciplinary approach is shaping a new paradigm where connectomics can guide pharmaceutical research toward treatments that are both more effective and more holistic.

2. Connectomics focuses on mapping neural connections to understand brain functions better. Can you elaborate on how this approach could redefine our understanding of neurological diseases and their treatment?

When we think of neurological diseases today, we often classify them based on visible symptoms or isolated structural damage in the brain. But the brain doesn’t operate in silos — it works as an interconnected network. A stroke, for example, doesn’t just affect one small region; it disrupts communication across circuits. Similarly, conditions like Alzheimer’s, depression, or epilepsy are not only about one “problem area” but about how different regions fail to coordinate. Connectomics gives us a way to see these diseases as disorders of connectivity rather than isolated defects. By mapping the “wiring diagram” of the brain, we can begin to understand why two patients with the same diagnosis might experience completely different symptoms — and why they respond differently to the same treatment. In practical terms, this means moving from a symptom-first approach to a mechanism-first approach. If we can identify which circuits are disrupted, therapies can be designed or selected to restore those pathways. That could completely change how we approach diagnosis, treatment planning, and even drug development.

3. How do you envision AI-driven connectomics influencing drug discovery and development? Are there any specific breakthroughs or innovations that stand out to you in this field?

Drug discovery has historically relied on trial and error — identify a molecule, test it, and see if it works. AI-driven connectomics allows us to flip this process. Instead of asking “Does this drug work?”, we can ask “Which circuits in the brain does this drug influence, and are those the circuits linked to the disease?” One breakthrough here is the ability to simulate how interventions ripple across brain networks before a single patient trial. Machine learning models can predict how altering a particular receptor or pathway might impact connectivity at the macro level. This dramatically reduces wasted effort and narrows the search for effective compounds. We’re also seeing advances in multimodal integration — combining genetic, imaging, and clinical data into unified connectomic maps. This enables us to link molecular action with system-level outcomes, bridging a gap that has long slowed progress in neuroscience-based drug discovery.

4. You’ve mentioned that understanding brain circuitry can help identify novel drug targets. Could you discuss how this process works in practical terms and what role machine learning plays in identifying these targets?

Today, large-scale connectomic networks—such as the default mode, salience, attention, memory, language, motor, and sensory networks—have been standardized using data from thousands of healthy controls. This allows us to compare patient data against these baselines and detect subtle changes or anomalies. Once identified, these network-level alterations can often be linked to specific neurotransmitter systems or shared cellular signaling pathways, which then emerge as potential drug targets. Machine learning strengthens this process by handling the complexity of these vast datasets, clustering patterns, and predicting which biological mechanisms are most relevant. It can also filter and rank candidate molecules, helping researchers prioritise the ones most likely to succeed. The beauty of AI is its ability to manage enormous variability and still find meaningful signals—something traditional methods struggle with. While training these models is essential, we are closer than ever to making AI-driven drug target discovery a practical reality

5. One of the key benefits of connectomics is its potential for personalized medicine. How can understanding individual brain connectivity lead to more effective and tailored treatments?

Two patients may carry the same diagnosis, but their brains may be “miswired” in entirely different ways. Connectomics makes this visible. If Patient A’s depression is linked to overactivity in one circuit while Patient B’s stems from disconnection in another, the same drug or therapy won’t work equally well for both. By mapping each individual’s brain network, we can design treatments tailored to their unique connectivity profile. This might mean selecting a drug more likely to restore balance in their specific circuit, adjusting dosage, or even pairing medication with targeted brain stimulation. The beauty of this approach is that it moves us beyond population averages. Instead of saying “this drug helps 40% of patients,” we can say “this drug is highly likely to help you, because we can see how it aligns with your brain’s functions.”

6. What are some of the challenges that pharmaceutical companies face in adopting connectomics-based strategies in drug development, and how can these challenges be overcome?

The biggest challenges are scale, cost, and mindset.

• Standardisation: Imaging and analysis methods still vary across labs, which makes it hard to compare results reliably.
• Awareness and acceptance: Pharma is traditionally focused on molecular targets and, in neurology or psychiatry, mostly tracks symptom outcomes rather than network-level changes. Shifting that mindset requires strong evidence.
• Data scale: High-quality brain imaging and connectomic datasets are resource-intensive, and drug discovery needs extensive validation.

To overcome these hurdles, collaboration between academia, pharma, and tech is essential. Advances in cloud computing and AI are already making large-scale data analysis more accessible, while standardised pipelines—something we at BrainSightAI are working on—can ensure consistency across sites. Most importantly, demonstrating clear clinical outcomes through early wins will be the tipping point that builds confidence and accelerates adoption of connectomics in drug development. We’ve already built baseline models and group-level datasets, and that foundation will help drive the transition forward.

7. Given your expertise in psychiatric disorders like schizophrenia and OCD, how can connectomics contribute to unraveling the complex neural circuits involved in these conditions?

Psychiatric disorders are especially difficult because their biological underpinnings are diffuse and invisible in traditional scans. With connectomics, we can see them not as “chemical imbalances” but as network disorders. In schizophrenia, for example, we consistently see abnormal connectivity between frontal and temporal lobes, which helps explain symptoms like disorganised thought and hallucinations. In OCD, hyperconnectivity between decision-making and error-monitoring circuits explains compulsive behaviors. By identifying these disrupted networks, we can better categorise subtypes of each disorder, predict treatment response, and even develop circuit-specific interventions. This brings much-needed biological objectivity to fields that have long been limited by symptom-based diagnoses.

8. Can you share some examples from your research where connectomics has made a tangible impact in improving clinical decision-making, particularly in psychiatric disorders?

In our research and pilot collaborations with hospitals and clinical teams, we’ve seen connectomics make a real difference, especially in difficult psychiatric cases where patients were resistant to medication and not showing improvement. By analysing brain activity and connectivity patterns, we can identify which networks are involved—whether memory, attention, salience, or others—and determine how they are being over- or under-utilised. For example, if a region within the memory network shows abnormal activity, and we know that this network interacts with anxiety circuits, it becomes a region of interest for targeted therapy. This insight allows doctors to either adjust medications based on the associated neurotransmitter pathways or refine cognitive and behavioural therapies. In practice, this has helped clinicians personalize treatments, making them more effective for patients who previously had limited options.

9. With the advent of AI in neuroscience, how do you foresee the integration of brain mapping technologies into routine clinical practices and pharmaceutical development pipelines?

With rising awareness, decreasing cost of imaging, and reduced stigma around mental health, brain mapping is on its way to becoming a routine part of preventive and clinical care. For example, in conditions like Alzheimer’s, functional changes can signal risk far earlier than symptoms appear, and since some FDA-approved drugs only work in early stages, brain mapping could make timely intervention possible.

I believe we’re moving toward a future where brain scans guided by AI will be as common as a blood test. Automated AI pipelines are reducing the need for manual effort, imaging is becoming more affordable, and regulatory frameworks are slowly adapting. In clinical practice, this means psychiatrists and neurologists would have more objectivity to guide treatment, rather than relying only on subjective reports. In pharmaceutical development, it offers a shift from measuring just symptom relief to tracking measurable changes in brain circuits—supporting precision medicine and faster, more reliable drug development.

Beyond drug discovery, brain mapping will also play an important role in monitoring disease progression and guiding neurorehabilitation. We’re already seeing its potential in tumor cases and radiation therapies, and it’s only a matter of time before the same becomes true for psychiatric and neurodegenerative disorders."

10. Personalized medicine, as you mentioned, could greatly benefit from connectomics. What are the ethical considerations of using brain connectivity data for drug development and personalized treatment plans?

The brain is the most personal organ — it defines who we are. Using brain connectivity data responsibly is therefore critical. Key concerns include:

• Privacy: Brain maps could, in theory, reveal vulnerabilities or predict disorders. Safeguarding this information is essential.
• Consent: Patients must fully understand how their data will be used, especially when shared across research and commercial partners.
• Equity: Advanced neuroimaging must not become available only to the privileged few; equitable access is vital for fairness.

Ethical frameworks need to evolve alongside technology, ensuring that the benefits of connectomics are delivered without compromising individual rights or deepening healthcare inequalities.

11. In your opinion, how can the pharmaceutical industry collaborate with AI-driven neuroscience companies to accelerate the development of novel therapies?

Collaboration works best when each side brings its strength. Pharma has decades of expertise in drug development, regulatory approval, and clinical trials. AI-driven neuroscience companies bring innovation in data analysis, imaging, and modeling. By working together, pharma can ground its drug discovery in real-world brain data, while startups can ensure their insights translate into therapies that scale globally. Co-developing trials that integrate connectomic biomarkers from the outset is one powerful way to accelerate progress.

12. What do you believe are the most promising areas of research in connectomics that could revolutionise the treatment of neurodegenerative diseases such as Alzheimer’s or Parkinson’s?

In Alzheimer’s, the most urgent need is early diagnosis and better disease management. Connectomics allows us to detect subtle network-level changes well before structural damage appears, opening the door for earlier intervention. We are already working on using these network changes to optimise management strategies in Alzheimer’s patients.
In Parkinson’s, mapping motor circuits provides powerful insights for both surgical and pharmacological approaches. For example, we collaborate with neurosurgeons to refine tractography and activity maps for deep brain stimulation, making the procedure more precise and effective. At the same time, these connectivity maps can guide pharmaceutical research by revealing whether motor circuit changes can be modulated through drugs to restore movement control.

Another transformative direction is combining connectomics with molecular biomarkers. While connectomics captures alterations in brain circuits, molecular biomarkers track underlying pathological processes. Together, this dual perspective could provide a comprehensive picture of disease progression and treatment response.

13. Looking ahead, what do you think the next decade holds for the intersection of connectomics, AI, and pharmaceutical development? What advancements do you anticipate?

Over the next decade, the practical integration of connectomics and AI into pharmaceutical development will focus on generating robust, reliable tools that complement existing biomarker strategies rather than replace them. Connectomics offers the unique ability to characterise changes in brain networks, providing deeper insight into disease mechanisms that symptom-based assessments cannot capture. By combining standardised brain mapping with large-scale datasets, we can identify reproducible network alterations associated with drug effects or disease progression.

For pharma, this means using connectomics as an additional objective layer in clinical trials to enhance patient stratification and track network-level drug impact more precisely. While AI will streamline the analysis of complex imaging data, these outputs must be rigorously validated and integrated with established molecular and clinical biomarkers to gain regulatory and clinical acceptance.

Achieving this requires close collaboration with regulatory bodies to establish clear standards and demonstrating early, clinically meaningful improvements through pilot studies. With consistent data pipelines, cross-site standardisation, and evidence-backed applications, connectomics can become a trusted element in drug development—accelerating decision-making, reducing late-stage failures, and ultimately improving therapeutic precision for neurological and psychiatric disorders.

14. Finally, what message would you give to the next generation of scientists and researchers interested in pursuing careers at the intersection of AI, neuroscience, and pharmaceutical innovation?

Neurotechnology is one of the most rewarding fields—both intellectually and personally. What you learn and discover in this space never goes to waste because every insight builds toward better understanding and better treatments for complex brain disorders. My message to the next generation is to stay interdisciplinary and patient. Breakthroughs happen where fields converge, not in isolation, and progress in neuroscience and AI can feel slow because the brain is incredibly complex. But every small step leads to a bigger leap in science and patient care. Most importantly, stay connected to the human side—behind every dataset is a person hoping for relief. If you keep that perspective, your work won’t just advance knowledge; it will truly change lives